Tadnersen

Cat. No.:	HY-132581
CAS No.:	2170507-65-8
Sequence:	RNA, ([2'-O-(2-methoxyethyl)]G-sp-[2'-O-(2-methoxyethyl)]m5C-[2'-O-(2-methoxyethyl)]m5C-[2'-O-(2-methoxyethyl)]m5C-sp-m5dC-sp-dT-sp-dA-sp-dG-sp-m5dC-sp-dG-sp-m5dC-sp-dG-sp-[2'-O-(2-methoxyethyl)]m5C-[2'-O-(2-methoxyethyl)]G-[2'-O-(2-methoxyethyl)]A-[2'-O-(2-methoxyethyl)]m5C-sp-[2'-O-(2-methoxyethyl)]m5U-sp-[2'-O-(2-methoxyethyl)]m5C) (ACI)
Target:	Others
Pathway:	Others
Storage:	-20°C, sealed storage, away from moisture
	* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

SOLVENT & SOLUBILITY

In Vitro	H_2O : ≥ 100 mg/mL
	* "≥" means soluble, but saturation unknown.

BIOLOGICAL ACTIVITY

Description	Tadnersen (BIIB078), an antisense oligonucleotide (ASO), selectively targets *C9ORF72* transcript variants 1 and 3 that carry the expansion[1].
In Vitro	Tadnersen (BIIB078) is an RNAse H oligomer that selectively inhibits mutant C9ORF72 transcripts. Tadnersen is used for the research of Amyotrophic Lateral Sclerosis (ALS)[2].
	MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Smeyers J, et al. C9ORF72: What It Is, What It Does, and Why It Matters. Front Cell Neurosci. 2021;15:661447. Published 2021 May 5.

[2]. Aoki Y, et al. Emerging Oligonucleotide Therapeutics for Rare Neuromuscular Diseases [published online ahead of print, 2021 Jun 3]. J Neuromuscul Dis. 2021;10.3233/JND-200560.